Invention Grant
- Patent Title: Engineered TSC2
-
Application No.: US16631069Application Date: 2018-07-13
-
Publication No.: US11639508B2Publication Date: 2023-05-02
- Inventor: David A. Kass , Mark J. Ranek , Kristen Kokkonen , Jonathan D. Powell , Chirag Patel
- Applicant: The Johns Hopkins University
- Applicant Address: US MD Baltimore
- Assignee: The Johns Hopkins University
- Current Assignee: The Johns Hopkins University
- Current Assignee Address: US MD Baltimore
- Agency: Fish & Richardson P.C.
- International Application: PCT/US2018/042142 WO 20180713
- International Announcement: WO2019/014624 WO 20190117
- Main IPC: C12N15/85
- IPC: C12N15/85 ; A61K35/17

Abstract:
Provided herein are engineered TSC2 polypeptides, and nucleic acid sequences encoding them, in which the ability of a serine residue to be phosphorylated is altered. In some aspects, the TSC2 serine residue cannot be phosphorylated (e.g., by substituting the serine residue with an alanine residue). In some aspects, the TSC2 serine acts as if it is constitutively phosphorylated (e.g., by substituting the serine residue with a glutamic acid residue). Also provided herein are engineered immune cells comprising altered TSC2 polypeptides or nucleic acid sequences encoding them, and methods of making and using such engineered immune cells.
Public/Granted literature
- US20200149062A1 ENGINEERED TSC2 Public/Granted day:2020-05-14
Information query
IPC分类: